Charles Schwab Investment Management Inc. Buys 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Charles Schwab Investment Management Inc. raised its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 712,811 shares of the company's stock after buying an additional 23,738 shares during the period. Charles Schwab Investment Management Inc. owned 0.82% of IDEAYA Biosciences worth $18,319,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company's stock worth $400,297,000 after purchasing an additional 1,365,570 shares during the last quarter. RA Capital Management L.P. purchased a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $42,681,000. Janus Henderson Group PLC increased its stake in shares of IDEAYA Biosciences by 26.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company's stock worth $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. Jennison Associates LLC increased its stake in shares of IDEAYA Biosciences by 136.6% during the 3rd quarter. Jennison Associates LLC now owns 972,266 shares of the company's stock worth $30,801,000 after purchasing an additional 561,404 shares during the last quarter. Finally, State Street Corp increased its stake in shares of IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock worth $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

Remove Ads

IDEAYA Biosciences Price Performance

NASDAQ:IDYA traded down $0.05 during trading hours on Friday, hitting $18.39. The stock had a trading volume of 1,881,739 shares, compared to its average volume of 823,642. The company has a 50 day simple moving average of $21.31 and a two-hundred day simple moving average of $26.52. IDEAYA Biosciences, Inc. has a one year low of $16.95 and a one year high of $44.42. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.57 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. Equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IDYA shares. Wedbush restated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Stephens restated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.